Krystal Biotech, Inc. (KRYS) Balance Sheet
As of 2026-06-30 (10-Q), Krystal Biotech, Inc. (KRYS) reported total assets of $1.5B, total liabilities of $141.5M and shareholders' equity of $1.4B, according to EquiReason's reading of its SEC filings. Cash and equivalents: $427.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KRYSKrystal Biotech, Inc.Follow KRYS — free
—
Price chart with a free account
- Market cap
- 9.2B
- P/E TTM
- 39.0
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2017 Dec 17 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 0.05 | 0.19 | 0.27 | 0.34 | 0.16 | 0.36 | 0.34 | 0.50 | 0.43 | |
| Short-term investments | — | 0.01 | 0.00 | 0.10 | 0.22 | 0.17 | 0.25 | 0.33 | 0.42 | |
| Receivables | — | — | — | — | 0.00 | 0.04 | 0.10 | 0.13 | 0.14 | |
| Inventory | — | — | — | — | 0.00 | 0.01 | 0.03 | 0.04 | 0.05 | |
| Current assets | 0.05 | 0.20 | 0.28 | 0.44 | 0.38 | 0.59 | 0.74 | 1.02 | 1.06 | |
| Total assets | 0.05 | 0.21 | 0.31 | 0.63 | 0.56 | 0.82 | 1.06 | 1.33 | 1.50 | |
| Current liabilities | 0.00 | 0.00 | 0.02 | 0.03 | 0.03 | 0.03 | 0.10 | 0.10 | 0.13 | |
| Long-term debt | 0.00 | — | — | — | — | — | — | — | — | |
| Total liabilities | 0.00 | 0.01 | 0.02 | 0.03 | 0.04 | 0.04 | 0.11 | 0.11 | 0.14 | |
| Shareholders' equity | 0.05 | 0.20 | 0.29 | 0.59 | 0.52 | 0.78 | 0.95 | 1.22 | 1.36 |
USD billions · SEC XBRL
Krystal Biotech, Inc. — questions
- How much cash does Krystal Biotech, Inc. have?
- $427.7M in cash and cash equivalents as of 2026-06-30.
- What are Krystal Biotech, Inc.'s total assets?
- $1.5B as of 2026-06-30.
- What is Krystal Biotech, Inc.'s shareholders' equity?
- $1.4B as of 2026-06-30.
Every figure on this page comes from Krystal Biotech, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.